COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

0.3% Sodium Hyaluronate in the Treatment of Dry Eye of Diabetic Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02595606
Recruitment Status : Unknown
Verified January 2016 by Wang Zhichong, Sun Yat-sen University.
Recruitment status was:  Recruiting
First Posted : November 3, 2015
Last Update Posted : January 12, 2016
Information provided by (Responsible Party):
Wang Zhichong, Sun Yat-sen University

Brief Summary:
A randomized parallel controlled study was designed to compare the efficacy of 0.3% Sodium Hyaluronate in the treatment of Dry Eye of diabetic patients.

Condition or disease Intervention/treatment Phase
Dry Eye Syndromes Diabetes Mellitus Drug: 0.3% Sodium Hyaluronate Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 60 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Treatment
Official Title: 0.3% Sodium Hyaluronate in the Treatment of Dry Eye of Diabetic Patients
Study Start Date : September 2015
Estimated Primary Completion Date : March 2016
Estimated Study Completion Date : March 2016

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: treatment group
treatment with 0.3% Sodium Hyaluronate, by five times a day, one or two drop each time
Drug: 0.3% Sodium Hyaluronate
five times per day for the intervention of eye drop

No Intervention: control group
without treatment

Primary Outcome Measures :
  1. ocular surface disease index [ Time Frame: up to 2 months ]
    pre-,1,4,8 weeks after the initiation of the study(the use of drug for experimental group)

Secondary Outcome Measures :
  1. tear break up time [ Time Frame: up to 2 months ]

  2. Schirmer' test [ Time Frame: up to 2 months ]
    test of tear secretion

  3. conjunctival goblet cells density [ Time Frame: up to 2 months ]
    indirect assessment of tear quality

  4. corneal fluorescein staining assessment [ Time Frame: up to 2 months ]
    assessment of the corneal invasion

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   17 Years to 70 Years   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. medical history of diabetes
  2. diagnosed with proliferative diabetic retinopathy
  3. diagnosed with dry eye
  4. not involvement in other drug experiment in the past 2 weeks
  5. vision acuity better than 0.1
  6. no local drug using history or with at least 2 weeks blanking period

Exclusion Criteria:

  1. allergy to any of the drug ingredient
  2. being or going to be pregnant or in lactation period
  3. with any other eye disease or other serious disease which might affect the trial or could not get in follow-up
  4. with any eye surgery history in the past six months
  5. usage of hormone for replacement therapy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02595606

Layout table for location contacts
Contact: Zhang Xiulan, M.D. 02087335367

Layout table for location information
China, Guangdong
Clinical Research Center Recruiting
Guangzhou, Guangdong, China, 510000
Contact: Wang Zhichong, M.D.    02087333391   
Contact: Gao Xinbo, M.D.    02087330484   
Sponsors and Collaborators
Sun Yat-sen University
Layout table for additonal information
Responsible Party: Wang Zhichong, cornea department chief, Sun Yat-sen University Identifier: NCT02595606    
Other Study ID Numbers: 03SHDD
First Posted: November 3, 2015    Key Record Dates
Last Update Posted: January 12, 2016
Last Verified: January 2016
Keywords provided by Wang Zhichong, Sun Yat-sen University:
dry eye syndromes
diabetes mellitus
Additional relevant MeSH terms:
Layout table for MeSH terms
Keratoconjunctivitis Sicca
Dry Eye Syndromes
Diabetes Mellitus
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Conjunctival Diseases
Eye Diseases
Corneal Diseases
Lacrimal Apparatus Diseases
Hyaluronic Acid
Adjuvants, Immunologic
Immunologic Factors
Physiological Effects of Drugs
Protective Agents